NCT00554086View on ClinicalTrials.gov

Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2010

Conditions
Prostate Cancer
Interventions
DRUG

Escalating dose of Casodex from 50mg daily to 150 mg daily

Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Canadian Urology Research Consortium

OTHER